Provided by Tiger Trade Technology Pte. Ltd.

Longeveron Inc

1.04
+0.109611.78%
Post-market: 1.02-0.0190-1.83%19:54 EDT
Volume:556.45K
Turnover:549.19K
Market Cap:30.45M
PE:-0.81
High:1.05
Open:0.9380
Low:0.9200
Close:0.9304
52wk High:1.83
52wk Low:0.4750
Shares:29.28M
Float Shares:25.19M
Volume Ratio:0.77
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2917
EPS(LYR):-2.6164
ROE:-164.75%
ROA:-81.27%
PB:5.37
PE(LYR):-0.40

Loading ...

Longeveron New Mri Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients With Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)

THOMSON REUTERS
·
Dec 02, 2025

Longeveron Highlights Laromestrocel Data Showing Reduced Brain Neuroinflammation in Mild Alzheimer’s Disease

Reuters
·
Nov 19, 2025

Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)

THOMSON REUTERS
·
Nov 19, 2025

Longeveron granted U.S. patent for administration of MSCs

TIPRANKS
·
Nov 12, 2025

Longeveron Granted U.S. Patent for Stem Cell Therapy Targeting Aging-Related Frailty

Reuters
·
Nov 12, 2025

Longeveron Granted U.S. Patent for Method of Treating Aging-Related Frailty in Patients With Inflammaging Using Its Proprietary Stem Cell Therapy

THOMSON REUTERS
·
Nov 12, 2025

Longeveron Inc - Patent Rights in U.S. Through 2038

THOMSON REUTERS
·
Nov 12, 2025

Longeveron Directors Khoso Baluch and Neha Motwani Resign

Reuters
·
Nov 12, 2025

Longeveron: Promising Outlook with Clinical Progress and Strategic Adjustments

TIPRANKS
·
Nov 07, 2025

Roth MKM Reaffirms Their Buy Rating on Longeveron (LGVN)

TIPRANKS
·
Nov 05, 2025

Longeveron Inc - on Track for Elpis Ii Results in Q3 2026 - SEC Filing

THOMSON REUTERS
·
Nov 05, 2025

Cellular therapy developer Longeveron's Q3 net loss widens

Reuters
·
Nov 05, 2025

Longeveron Q3 EPS USD -0.39

Reuters
·
Nov 05, 2025

Longeveron Q3 Operating Expenses USD 7.435 Million

THOMSON REUTERS
·
Nov 05, 2025

Longeveron Q3 EPS $(0.39) Misses $(0.26) Estimate, Sales $137.000K Miss $284.667K Estimate

Benzinga
·
Nov 05, 2025

Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

GlobeNewswire
·
Oct 28, 2025

Longeveron Inc. Files Initial Statement of Beneficial Ownership for Director George A. Paletta Jr

Reuters
·
Oct 28, 2025

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

GlobeNewswire
·
Oct 27, 2025

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

GlobeNewswire
·
Oct 06, 2025

Longeveron Inc. Files Initial Beneficial Ownership Statement for CEO James Nathaniel Powell

Reuters
·
Oct 02, 2025